MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Coherus Biosciences Company Profile (NASDAQ:CHRS)

Consensus Ratings for Coherus Biosciences (NASDAQ:CHRS) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $35.33 (130.64% upside)

Analysts' Ratings History for Coherus Biosciences (NASDAQ:CHRS)
Show:
DateFirmActionRatingPrice TargetActions
3/1/2016JPMorgan Chase & Co.Lower Price TargetOverweight$37.00 -> $35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/19/2016Credit SuisseInitiated CoverageOutperform$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/23/2015BarclaysInitiated CoverageOverweight$46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/1/2014Cowen and CompanyInitiated CoverageOutperform$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Coherus Biosciences (NASDAQ:CHRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/9/2016Q1($1.42)($1.67)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q4($1.74)($1.35)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q3($1.86)$16.10 million$7.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($1.56)$488.15 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($1.22)$488.15 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/23/2015Q414($0.46)($1.47)$6.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/15/2014Q212($1.79)$16.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/27/2012($0.02)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/1/2011($0.09)($0.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/1/2011$0.01($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
6/2/2011$0.12$0.17ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/24/2011($0.19)($0.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Coherus Biosciences (NASDAQ:CHRS)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Coherus Biosciences (NASDAQ:CHRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Coherus Biosciences (NASDAQ:CHRS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/1/2016Alan C HermanInsiderSell4,250$18.67$79,347.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2016Peter K WatlerInsiderSell12,000$20.00$240,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016Alan C HermanInsiderSell4,250$19.20$81,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2016Alan C HermanInsiderSell2,000$15.02$30,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Alan C. HermaninsiderSell11,333$29.49$334,210.17View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2015Christos RichardsDirectorSell15,000$27.49$412,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Alan C. HermaninsiderSell18,416$28.71$528,723.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Alan C. HermaninsiderSell4,250$18.98$80,665.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Alan C. HermaninsiderSell11,333$27.39$310,410.87View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Mats WahlstromDirectorSell6,373$33.50$213,495.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Mats WahlstromDirectorSell8,028$33.91$272,229.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2015Mats WahlstromDirectorSell116,554$34.24$3,990,808.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015August J TroendleDirectorSell250,000$26.68$6,670,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Eli & Co LillyInsiderBuy164,963$13.50$2,227,000.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Coherus Biosciences (NASDAQ:CHRS)
DateHeadline
06/25/16 07:04 AMCoherus BioSciences, Inc. (NASDAQ:CHRS) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 10:15 AM3 Biotech Stocks to Buy in the Wake of the Brexit Vote -
06/24/16 04:48 AMCovering the Bases on Coherus BioSciences, Inc. (NASDAQ:CHRS): Where is the Stock Going? - Press Telegraph
06/23/16 04:38 PMNew Broker Ratings For Coherus BioSciences, Inc. (CHRS) - FTSE News
06/19/16 03:03 PMCoherus BioSciences, Inc. (CHRS) Analyst Price Targets For The Coming Week - Fiscal Standard
06/14/16 03:07 PMCOHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/13/16 02:40 PMCoherus BioSciences (CHRS) Announces Favorable PTAB Decision for IPR Petitions (ABBV) - StreetInsider.com
06/13/16 01:29 PMCoherus BioSciences Provides Update on IPRs - [at noodls] - REDWOOD CITY, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that ...
06/11/16 11:26 AMCoherus Presents Study Results Demonstrating Equivalence of its CHS-0214 Biosimilar to Etanercept: Biosimilar to etanercept meets primary endpoint
06/11/16 11:26 AMCoherus BioSciences (CHRS) Announces Results of Study Demonstrating CHS-0214 Equivalence to Enbrel
06/10/16 03:15 PMTrend Of Rating Given To Coherus BioSciences, Inc. (NASDAQ:CHRS) - Investor Newswire
06/10/16 03:15 PMCoherus BioSciences (CHRS) Announces Results of Study Demonstrating CHS-0214 Equivalence to Enbrel - StreetInsider.com
06/10/16 11:19 AMCoherus Presents Study Results Demonstrating Equivalence of its CHS-0214 Biosimilar to Etanercept - [at noodls] - REDWOOD CITY, Calif., June 10, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced the release ...
06/08/16 11:46 AMCOHERUS BIOSCIENCES INC. (NASDAQ:CHRS) Financial Condition Compared to S&P 500 - CML News
06/06/16 07:06 AMCoherus Biosciences Incorporated (NASDAQ:CHRS) Sellers Increased By 3.65% Their Shorts - HNN
06/06/16 07:06 AMStock Review and Earnings Check on Coherus BioSciences, Inc. (NASDAQ:CHRS) - HNN
06/04/16 11:45 AMStocks Earnings Report: Coherus Biosciences, Inc. (NASDAQ:CHRS), Associated Banc-Corp (NYSE:ASB) - Beacon Chronicle
06/04/16 11:45 AM4250 Shares of Coherus Biosciences Inc (CHRS) Stock are sold by Alan C. Herman - Let Me Know About This
06/03/16 03:07 PMCOHERUS BIOSCIENCES, INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Other Events, Financial S -
06/03/16 10:36 AMShare Rating Focus on Coherus BioSciences, Inc. (NASDAQ:CHRS) - HNN
06/03/16 08:25 AMCoherus BioSciences to Present at Jefferies 2016 Healthcare Conference on June 8 - [at noodls] - REDWOOD CITY, Calif., June 03, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that ...
06/01/16 09:21 PMCoherus Biosciences Incorporated (NASDAQ:CHRS) Short Interest Increased By 3.65% - HNN - Coherus Biosciences Incorporated (NASDAQ:CHRS) Short Interest Increased By 3.65%HNNAbout 597,035 shares traded hands or 49.34% up from the average. Coherus Biosciences Inc (NASDAQ:CHRS) has declined 24.37% since October 23, 2015 and is downtrending. It has underperformed by 25.42% the S&P500. Coherus BioSciences, Inc. is a ...
06/01/16 11:49 AMStrong Sell Calls Count For Coherus BioSciences, Inc. (NASDAQ:CHRS) At 0 - Investor Newswire - Strong Sell Calls Count For Coherus BioSciences, Inc. (NASDAQ:CHRS) At 0Investor NewswireThe Sell calls on Coherus BioSciences, Inc. (NASDAQ:CHRS) were 0. Two months earlier 3 were the Strong Buy calls whereas Strong Sell calls were 0. During this period, the hold calls were 0. The buy recommendations were 0 and sell calls count was 0.and more »
05/30/16 09:09 PMCoherus BioSciences, Inc. (NASDAQ:CHRS) Quarterly EBIT At $-64.352 Millions - Stocks Daily - Coherus BioSciences, Inc. (NASDAQ:CHRS) Quarterly EBIT At $-64.352 MillionsStocks DailyFor the fiscal ended 2016-03-31, Coherus BioSciences, Inc. (NASDAQ:CHRS)comprehensive income was $-0.401 millions. The figure, for the quarter ended 2016-03-31 was $-0.401 millions. For the fiscal closed 2016-03-31, Coherus BioSciences, Inc.and more »
05/29/16 01:39 PMHow Many Coherus Biosciences Inc (NASDAQ:CHRS)'s Analysts Are Bullish? - HNN - How Many Coherus Biosciences Inc (NASDAQ:CHRS)'s Analysts Are Bullish?HNNOut of 4 analysts covering Coherus Biosciences (NASDAQ:CHRS), 0 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. Coherus Biosciences has been the topic of 3 analyst reports since September 3, 2015 according to StockzIntelligence ...and more »
05/28/16 01:12 PMStock Rating Review for Coherus BioSciences, Inc. (NASDAQ:CHRS) - Wall Street Hints and News - Stock Rating Review for Coherus BioSciences, Inc. (NASDAQ:CHRS)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1 on shares of Coherus BioSciences, Inc. (NASDAQ:CHRS). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus ...and more »
05/28/16 01:12 PMCoherus BioSciences (CHRS) Issued Three U.S. Patents Related to CHS-1420 - StreetInsider.com - Coherus BioSciences (CHRS) Issued Three U.S. Patents Related to CHS-1420StreetInsider.comCoherus BioSciences, Inc. (Nasdaq: CHRS) announced that the United States Patent and Trademark Office (USPTO) issued to Coherus U.S. Patents 9,340,611; 9,340,612 and 9,346,880. These patents generally concern formulations of adalimumab, the ...Coherus BioSciences, Inc. (CHRS) Updated Analyst CoverageRisers & FallersCoherus BioSciences, Inc. (NASDAQ:CHRS) Closes At $18.01Enterprise LeaderCoherus BioSciences, Inc. (NASDAQ:CHRS) Quarterly EPS From Continuing Operations Stands At $-1.6763Investor NewswireMarket Digest -Sonoran Weekly Reviewall 8 news articles »
05/26/16 03:26 PMCOHERUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Sta -
05/26/16 02:07 PMCoherus BioSciences Advances Differentiated IP Strategy for Humira Market Access - [at noodls] - REDWOOD CITY, Calif., May 26, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that the ...
05/26/16 01:15 PMTarget Check and Stock Performance Recap Coherus BioSciences, Inc. (NASDAQ:CHRS) - Wall Street Hints and News - Target Check and Stock Performance Recap Coherus BioSciences, Inc. (NASDAQ:CHRS)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Coherus BioSciences, Inc.and more »
05/25/16 03:07 PMCOHERUS BIOSCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/23/16 10:53 AMCoherus BioSciences Prices 3.5 Million Shares At $18.00/Share -
05/23/16 08:36 AMCoherus Prices Public Offering of Common Stock - [at noodls] - REDWOOD CITY, Calif., May 23, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced the pricing ...
05/23/16 05:26 AMCoherus Announces Proposed Public Offering of Common Stock - [at noodls] - REDWOOD CITY, Calif., May 23, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced it has ...
05/18/16 12:04 PMCOHERUS BIOSCIENCES, INC. Financials -
05/17/16 03:06 PMAbbVie’s Biggest Drug Gets Patent Setback; Stock Tumbles -
05/17/16 02:35 PMAbbVie's Patent Dam Springs a Leak -
05/17/16 02:02 PM[$$] Patent Office to Review a Regimen of AbbVie's Humira -
05/17/16 10:26 AMWhy AbbVie is Getting Hammered -
05/17/16 10:12 AMCoherus says U.S. Patent Office to review AbbVie's Humira -
05/17/16 10:02 AMCoherus BioSciences Provides Update on ‘135 IPR - [at noodls] - REDWOOD CITY, Calif., May 17, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it ...
02/26/16 12:26 PMCoherus BioSciences, Inc. (CHRS) Updated Price Targets - Share Trading News - Coherus BioSciences, Inc. (CHRS) Updated Price TargetsShare Trading NewsRecently analysts working for a veriety of stock market brokerages have changed their consensus ratings and price targets on shares of Coherus BioSciences, Inc. (CHRS). The most recent broker reports which have been released note that 0 analysts have a ...and more »
02/26/16 08:30 AMCoherus BioSciences to Present at Cowen and Company Healthcare Conference on March 8 - [GlobeNewswire] - REDWOOD CITY, Calif., Feb. 26, 2016-- Coherus BioSciences, Inc., a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will present at the Cowen and ...
02/15/16 08:30 AMCoherus BioSciences to Report Fourth Quarter and Year End 2015 Financial Results on February 29 - [GlobeNewswire] - REDWOOD CITY, Calif., Feb. 15, 2016-- Coherus BioSciences, Inc., a leading pure-play, global biosimilar company with late-stage clinical products, today announced that it has scheduled a conference call ...
02/14/16 01:52 PMCoherus Biosciences Incorporated (NASDAQ:CHRS) Shorts Decreased by 5.62% After Short Covering - fdanewsalert.com - Motley FoolCoherus Biosciences Incorporated (NASDAQ:CHRS) Shorts Decreased by 5.62% After Short Coveringfdanewsalert.comThe short interest to Coherus Biosciences Incorporated's float is 14.35%. The stock increased 2.02% or $0.27 on February 12, hitting $13.61. About 228,557 shares traded hands. Coherus Biosciences Inc (NASDAQ:CHRS) has declined 58.83% since July 10, ...Insider Selling: Coherus Biosciences Inc (CHRS) Insider Sells $30040.00 in StockFinancial Market Newsall 4 news articles »
02/12/16 12:42 PMWhy Coherus BioSciences Plunged 37% in January -
02/07/16 01:23 PMCommit To Purchase Coherus BioSciences At $12.50, Earn 37.6% Annualized Using Options - Investors considering a purchase of Coherus BioSciences Inc (CHRS) shares, but cautious about paying the going market price of $14.47/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put ...
02/05/16 08:30 AMCoherus BioSciences to Present at Bloomberg Intelligence Healthcare Event on February 12th - [GlobeNewswire] - REDWOOD CITY, Calif., Feb. 05, 2016-- Coherus BioSciences, Inc., a leading pure-play, global biosimilars company with late-stage clinical products, today announced that Denny Lanfear, President and Chief ...
02/04/16 01:50 PMCoherus Biosciences Inc Can't Burn Your Short Portfolio. Just Reaches All-Time Low - WallStreet.org - Coherus Biosciences Inc Can't Burn Your Short Portfolio. Just Reaches All-Time LowWallStreet.orgThe stock of Coherus Biosciences Inc (NASDAQ:CHRS) reached all time low today, Feb, 4 and still has $11.99 target or 6.00% below today's $12.75 share price. This indicates more downside for the $510.27M company. This technical setup was reported by ...and more »
02/02/16 01:30 PMCoherus BioSciences (CHRS) Annoucnes CHS-1701 Immunogenicity Study Met All Endpoints - StreetInsider.com - Coherus BioSciences (CHRS) Annoucnes CHS-1701 Immunogenicity Study Met All EndpointsStreetInsider.comCoherus BioSciences, Inc. (NASDAQ: CHRS) announced that CHS-1701, a proposed biosimilar of Neulasta® (pegfilgrastim), met both primary endpoints in a double-blind, randomized, two-period, parallel-arm clinical study in 303 healthy subjects. This study ...Coherus Announces the Appointment of Jim Daly, Executive Chairman, Commercial Adviso...CNNMoneyCoherus Announces the Appointment of Jim Daly, Executive Chairman, Commercial Advisory CommitteeEconoTimesall 13 news articles »
About Coherus Biosciences

Coherus Biosciences logoCoherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial. Its long-acting granulocyte colony-stimulating factor (G-CSF) product candidate, CHS-1701, is a pegfilgrastim (Neulasta) biosimilar. Its clinical-stage pipeline consists of two anti-Tumor Necrosis Factors (anti-TNFs).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CHRS
  • CUSIP:
Key Metrics:
  • Previous Close: $16.47
  • 50 Day Moving Average: $17.42
  • 200 Day Moving Average: $18.43
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $599.64M
  • Current Quarter EPS Consensus Estimate: $-5.90 EPS
Additional Links:
Coherus Biosciences (NASDAQ:CHRS) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha